Rodos BioTarget

company

About

Rodos BioTarget (RBT) is a biopharmaceutical company developing a targeted drug delivery platform, TargoSphere®.

  • 1 - 10

Details

Last Funding Type
Series Unknown
Last Funding Money Raised
€2.60M
Industries
Biopharma,Biotechnology,Pharmaceutical
Founded date
Jan 1, 2008
Number Of Employee
1 - 10
Operating Status
Active

Rodos BioTarget (RBT) is a biopharmaceutical company developing a targeted drug delivery platform. RBT’s patented TargoSphere® technology enables carrying a broad range of active agents selectively into the center of the immune response - i.e., directly into antigen-presenting cells.

RBT currently applies its TargoSphere® technology successfully in various models of infectious diseases caused by viruses like HCV/ Hepatitis C and HIV/ AIDS and by bacteria like in Tuberculosis, Legionellosis, and MRSA. Yet, any disorder that goes along with either overshooting or insufficient immunity caused by antigen-presenting cells - like chronic inflammations, cancers, allergies, and autoimmune diseases - may be addressed by RBT’s TargoSphere® technology.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
€2.60M
Rodos BioTarget has raised a total of €2.60M in funding over 2 rounds. Their latest funding was raised on Apr 17, 2013 from a Series Unknown round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Apr 17, 2013 Series Unknown €2.60M 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
Rodos BioTarget is funded by 1 investors. ERP Startfonds are the most recent investors.
Investor Name Lead Investor Funding Round
ERP Startfonds Series Unknown